Acute Myeloid Leukemia in Remission Clinical Trial
Official title:
Impact of Aerobic Versus Resistive Training on Functional Capacity in Acute Myeloid Leukemia Survivors; a Comparative Study
NCT number | NCT04617145 |
Other study ID # | MA201918 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | April 1, 2018 |
Est. completion date | October 1, 2020 |
Verified date | October 2020 |
Source | Cairo University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Sixty patients with AML from both sexes aged from 35-45 years were selected from hematology department in Nasser Institute Hospital where the study was conducted. Patients were randomly assigned into two groups equal in number. Group (A) underwent aerobic exercises in the form of cycling with 50-60% of maximum heart rate. Group (B) underwent resistive training conducted in the form of a series of exercises using free weights, and dumbles. Sessions were conducted three times /week for eight weeks. Six minutes' walk test (6MWT), 10 repetitions maximum test (10 RM), ventilatory function test, fatigue and quality of life (QOL) scales were used to assess functional capacity in both groups.
Status | Completed |
Enrollment | 60 |
Est. completion date | October 1, 2020 |
Est. primary completion date | June 2, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 35 Years to 45 Years |
Eligibility | Inclusion Criteria: - Acute myeloid leukemia survivors from both sexes - Their age ranged from 35-45 years. - Patients were in remission stage contains less than 5% blast cells in their bone marrow, absolute neutrophil count (>1000/microL), platelet count(>100,000/microL),and independence from red cell transfusion. Exclusion Criteria: - Extramedullary leukemia - musculoskeletal deformities - severe anemia (hemoglobin less than 8g/dl). - Autoimmune thrombocytopenia (platelets less than 10000UL or leucocytes count more than 3000UL). |
Country | Name | City | State |
---|---|---|---|
Egypt | Faculty of Physical Therapy | Giza | Cairo |
Lead Sponsor | Collaborator |
---|---|
Cairo University |
Egypt,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Six minutes walking Distance | which used to measure the distance the patient was able to walk over a total of six minutes According to American thorax society guidelines; patients were instructed to walk as fast as long as possible , in a 30 meters obstacle free corridor limited by turnaround cones and distance was calculated | It is performed before and after the study(8 weeks interval) for both groups | |
Primary | 10 repetition maximum test | which the greatest amount of weight a person can lift number of times. The amount of weight that can be lifted exactly 10 times is 10 RM | It is performed before and after the study(8 weeks interval) for both groups | |
Primary | Vital capacity | was measured by using electronic spirometry used to conduct ventilatory function testing | It is performed before and after the study(8 weeks interval) for both groups | |
Secondary | Maximum oxygen consumption | Results of (6MWT) was used to calculate Vo2 max by using Cahalin equation as follows; Vo2 max = 0.03x distance in meters +3.98, in which distance is obtained from (6MWT) | It is performed before and after the study(8 weeks interval) for both groups | |
Secondary | Fatigue assessment scale (FAS) | FAS is a 10-item scale evaluating symptoms of chronic fatigue | It is performed before and after the study(8 weeks interval) for both groups | |
Secondary | Quality of life questionnaire (QOL) | was used to evaluate the quality of life before and after training for both groups.The Quality of Life Instrument (CANCER PATIENT/CANCER SURVIVOR VERSION) is a forty one-item ordinal scale. The scoring should be based on a scale of 0 = worst outcome to 10 = best outcome | It is performed before and after the study(8 weeks interval) for both groups |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03887156 -
Evaluation of a Donor Testing Kit for the Prediction of AGVHD in Patient Receiving a Peripheral Blood Stem Cell Allograft
|
Phase 2/Phase 3 | |
Recruiting |
NCT05917405 -
Study Comparing the Efficacy of 2 RIC Regimens (Clofarabine vs Fludarabine) in Adults With AML Eligible to Allo-SCT
|
Phase 2 | |
Recruiting |
NCT04062266 -
AZA + Venetoclax as Maintenance Therapy in Patients With AML in Remission
|
Phase 2 | |
Recruiting |
NCT04490707 -
Study of Azacytidine Combined With Lenalidomide As Maintenance Therapy Based on MRD Monitoring in AML
|
Phase 3 | |
Terminated |
NCT03272633 -
Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies
|
Early Phase 1 | |
Active, not recruiting |
NCT00075478 -
Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
|
Phase 3 | |
Active, not recruiting |
NCT03697707 -
Efficacy and Safety of Immunotherapy With Allogeneic Dendritic Cells, DCP-001, in Patients With Acute Myeloid Leukaemia
|
Phase 2 | |
Active, not recruiting |
NCT02506933 -
Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant
|
Phase 2 | |
Recruiting |
NCT03286530 -
Ruxolitinib + Allogeneic Stem Cell Transplantation in AML
|
Phase 2 | |
Withdrawn |
NCT02528877 -
Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With Myelofibrosis
|
Phase 1 | |
Active, not recruiting |
NCT01894477 -
Treo/Flu/TBI With Donor Stem Cell Transplant for Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
|
Phase 2 | |
Recruiting |
NCT04232241 -
Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia
|
Phase 2 | |
Active, not recruiting |
NCT02566304 -
Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
|
Phase 2 | |
Active, not recruiting |
NCT01619761 -
NK Cells in Cord Blood Transplantation
|
Phase 1 | |
Terminated |
NCT01028716 -
Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
|
Phase 2 | |
Recruiting |
NCT05794880 -
MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing
|
N/A | |
Completed |
NCT02083250 -
Fludarabine Phosphate, Clofarabine, and Busulfan With Vorinostat in Treating Patients With Acute Leukemia in Remission or Relapse Undergoing Donor Stem Cell Transplant
|
Phase 1 | |
Active, not recruiting |
NCT02446964 -
Total Marrow and Lymphoid Irradiation and Chemotherapy Before Donor Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Leukemia
|
Phase 1 | |
Recruiting |
NCT04747002 -
Investigator-initiated Clinical Trial (Phase II) of Cancer Vaccine "Dainippon Sumitomo Phama(DSP)-7888" for Acute Myeloid Leukemia Patients.
|
Phase 2 | |
Completed |
NCT01823198 -
Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies
|
Phase 1/Phase 2 |